Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →What's hot!
View all perspectives
What's Hot
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed chimeric antigen receptor T (CAR-T) cell therapy may be an effective approach.
Jiha Lee JihaRheum
1 week 2 days ago
Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 2 days ago
#EULAR2026 POS0044 TO ASPIRIN OR NOT in asymptomatic antiphospholipid antibodies (aPL) carriers? A study in Spain reported 4.6% VTE & 4.1% ATE.
-Aspirin reduced thrombosis without increasing bleeding risk in asymptomatic aPL inc. those <3 lab points (isolated LA) @RheumNow https://t.co/NyVjAfjAKd
sheila RHEUMarampa
1 week 2 days ago
SLE & Dengue infxn?
This pop’n study from Brazil showed that #SLE pts who developed #dengue had sig. higher rates of mortality, DHF & hospital stay length vs. gen popn
These factors were found to have strong independent assoc w/SLE.
Abs010 @rheumnow #EULAR2026 https://t.co/DTDPiQRlAf
Jiha Lee JihaRheum
1 week 2 days ago
IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045
Antoni Chan MD (Prof) synovialjoints
1 week 2 days ago
What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 2 days ago
#EULAR2026 POS0440 1-Year Open Label Extension Study of 6-monthly Inebilizumab, a CD19 depleter in #IgG4 disease:
-No flare in INEB group; 6% flare in PBO-INEB
-10.9% serious infections
-1 pt discontinued due to low IgG
Interested to see longer-term safety data @RheumNow https://t.co/PPUw81T8DZ
Nelly ZIADE 🍀 Nellziade
1 week 2 days ago
What’s in the pipeline for #psoriatic_arthritis treatment?
A special focus on Tyk2 inhibitors
WIN session at #EULAR2026
@RheumNow https://t.co/dDJtmdx9xU
Aurelie Najm AurelieRheumo
1 week 2 days ago
What is new in PsA?
Dennis McGonagle's take at #EULAR2026
-a strong year for discovery in mechanisms of transition from PSO to PsA
-publication of the first single cell atlas Enthesis
-Better understanding of VTE mechanisms in JAKi in PsA
-clinical aspects of Axial involvement https://t.co/v9cfn1y4fH
sheila RHEUMarampa
1 week 2 days ago
Pts with AIIRD carry a high risk & burden of infection due to immune dysregulation, comorbids, GC/DMaRD use.
As a rheumatologist, do you vaccinate your patients?
#EULAR2026 @RheumNow
Dr. John Cush RheumNow
1 week 2 days ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
sheila RHEUMarampa
1 week 2 days ago
Prof. Pedro Machado shares this important slide on a quick guide to #vaccination in patients w/ RMDs highlighting which vaccines are universally indicated, accdg to epidemiologic risk and w/ CIs.
#EULAR2026 @RheumNow https://t.co/JmTSC1uaph
sheila RHEUMarampa
1 week 2 days ago
#Vaccination in Rheum
📍Hold MTX 1-2wks post vax
📍For Bcell depleters, timing is based on B-cell repop’n kinetics, not fixed calendar intervals.
THM: Assess vax need at dx, vax w/o delay
#EULAR2026 @RheumNow https://t.co/6ptl8gyBLR
Md Yuzaiful Md Yusof Yuz6Yusof
1 week 2 days ago
#EULAR2026 POS0438 In Part A (Phase II) RCT of Cutaneous #lupus, Litifilimab, a BDCA2 mAb improved CLASI-A vs PBO at Week 16.
-Improvement as early as Week 4
-Low viral infections. Common AE: nasopharyngitis & headache.
-Interested to see results of Part B (phase III) @RheumNow https://t.co/2zzHd9NgBi
